Résultats de la recherche - David Nathanson
- Résultat(s) 1 - 20 résultats de 26
- Aller à la page suivante
-
1
Insights into the mechanisms of lymph node metastasis par David Nathanson
Publié 2003Revisão -
2
-
3
Clinicopathological Evaluation of the Potential Anatomic Pathways of Systemic Metastasis from Primary Breast Cancer Suggests an Orderly Spread Through the Regional Lymph Nodes par David Nathanson, S., Leonard-Murali, Shravan, Burmeister, Charlotte, Susick, Laura, Baker, Patricia
Publié 2020Texte -
4
-
5
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality par Jan W. Eriksson, Johan Bodegård, David Nathanson, Marcus Thuresson, Thomas Nyström, Anna Norhammar
Publié 2016Artigo -
6
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 200... par Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, Jan W. Eriksson, David Nathanson
Publié 2016Artigo -
7
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and se... par Thomas Nyström, Johan Bodegård, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W. Eriksson
Publié 2016Artigo -
8
Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type... par Thomas Nyström, Johan Bodegård, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W. Eriksson
Publié 2017Artigo -
9
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study... par Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, David Nathanson, Jan W. Eriksson
Publié 2019Artigo -
10
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety par David Nathanson, Bengt Ullman, Ulrika Löfström, Anders Hedman, Mats Frick, Åke Sjöholm, Thomas Nyström
Publié 2012Artigo -
11
Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive cont... par David Nathanson, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Jan Bolinder, Katarina Eeg‐Olofsson
Publié 2021Artigo -
12
Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population–based case–control study par Henrik Falhammar, Jonatan D. Lindh, Jan Calissendorff, Shermineh Farmand, Jakob Skov, David Nathanson, Buster Mannheimer
Publié 2018Artigo -
13
History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks i... par Viveca Ritsinger, Johan Bodegård, Robin Kristófi, Marcus Thuresson, David Nathanson, Thomas Nyström, Jan W. Eriksson, Anna Norhammar
Publié 2023Artigo -
14
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study par Robin Kristófi, Johan Bodegård, Anna Norhammar, Marcus Thuresson, David Nathanson, Thomas Nyström, Kåre I. Birkeland, Jan W. Eriksson
Publié 2021Artigo -
15
Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization par Vladimer Darsalia, Sansan Hua, Martin Larsson, Carina Mallard, David Nathanson, Thomas Nyström, Åke Sjöholm, Maria E. Johansson, Cesare Patrone
Publié 2014Artigo -
16
Factors Prognostic for Survival in Patients with Malignant Melanoma Spread to the Regional Lymph Nodes par Charles D. Callery, Alistair J. Cochran, Denise J. Roe, William V. Rees, S. David Nathanson, Jacqueline Benedetti, Robert M. Elashoff, Donald L. Morton
Publié 1982Artigo -
17
-
18
An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis par Gabi Tarcic, Shlomit Boguslavsky, Jean Wakim, Tai Kiuchi, A.H. Liu, Felicia Reinitz, David Nathanson, Takamune Takahashi, Paul S. Mischel, Tony Ng, Yosef Yarden
Publié 2009Artigo -
19
Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin par Grażyna Lietzau, William Davidsson, Claes‐Göran Östenson, Fausto Chiazza, David Nathanson, Hiranya Pintana, Josefin Skogsberg, Thomas Klein, Thomas Nyström, Vladimer Darsalia, Cesare Patrone
Publié 2018Artigo -
20
Outils de recherche:
Sujets similaires
Medicine
Internal medicine
Diabetes mellitus
Endocrinology
Type 2 diabetes
Cancer
Breast cancer
Population
Biology
Cancer research
Confidence interval
Disease
Engineering
Environmental health
Mechanical engineering
Stroke (engine)
Cohort
Hazard ratio
Pathology
Proportional hazards model
Dapagliflozin
Gene
Genetics
Insulin
Metastasis
Myocardial infarction
Oncology
Pediatrics
Pharmacology
Receptor